Alpine Immune End Davoceticept Study Enrollment After 2nd Patient Death

By Colin Kellaher

Alpine Immune Sciences Inc. on Monday said it has voluntarily ended enrollment in a pair of studies of its davoceticept drug candidate following the death of a second patient in one of the studies.

The Seattle clinical-stage immunotherapy company said the patient, who was enrolled in a study of davoceticept in combination with Merck & Co.'s cancer drug Keytruda, died of cardiogenic shock after receiving one dose of each drug.

The U.S. Food and Drug Administration earlier this year had placed a partial clinical hold on the combination study due to a death attributed to cardiogenic shock, but the hold was lifted in early May.

Alpine said it is conducting a comprehensive assessment of all participants in both studies, and that it will now focus on the pursuit of expedited development plans for ALPN-303 in multiple autoimmune and inflammatory indications.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

October 24, 2022 08:06 ET (12:06 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.